48.33
前日終値:
$47.93
開ける:
$48.59
24時間の取引高:
1.57M
Relative Volume:
0.74
時価総額:
$7.58B
収益:
$1.17B
当期純損益:
$150.71M
株価収益率:
51.41
EPS:
0.94
ネットキャッシュフロー:
$245.03M
1週間 パフォーマンス:
+2.13%
1か月 パフォーマンス:
-4.30%
6か月 パフォーマンス:
-35.87%
1年 パフォーマンス:
-38.51%
Bio Techne Corp Stock (TECH) Company Profile
TECH を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
TECH
Bio Techne Corp
|
48.33 | 7.42B | 1.17B | 150.71M | 245.03M | 0.94 |
![]()
ONC
Beone Medicines Ltd Adr
|
246.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
447.09 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
77.49 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-09 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
2025-03-18 | 開始されました | Evercore ISI | Outperform |
2025-02-19 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
2024-02-08 | 開始されました | Scotiabank | Sector Outperform |
2024-02-02 | ダウングレード | Stifel | Buy → Hold |
2023-12-07 | 開始されました | UBS | Buy |
2023-08-28 | 開始されました | William Blair | Outperform |
2023-01-10 | アップグレード | Wells Fargo | Underweight → Equal Weight |
2022-12-14 | 開始されました | Deutsche Bank | Buy |
2022-12-12 | アップグレード | Citigroup | Neutral → Buy |
2022-12-07 | 開始されました | RBC Capital Mkts | Sector Perform |
2022-08-25 | 開始されました | Credit Suisse | Outperform |
2022-04-25 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
2021-09-15 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
2021-03-08 | アップグレード | Stephens | Equal-Weight → Overweight |
2021-02-23 | アップグレード | Stifel | Hold → Buy |
2021-01-25 | 繰り返されました | The Benchmark Company | Buy |
2020-11-10 | 開始されました | KeyBanc Capital Markets | Sector Weight |
2020-09-30 | 開始されました | Atlantic Equities | Overweight |
2020-07-15 | ダウングレード | Stephens | Overweight → Equal-Weight |
2020-05-27 | ダウングレード | Stifel | Buy → Hold |
2020-05-14 | 開始されました | The Benchmark Company | Buy |
2020-01-08 | 再開されました | Stephens | Overweight |
2020-01-08 | 開始されました | Wells Fargo | Equal Weight |
2020-01-07 | 開始されました | Citigroup | Neutral |
2019-11-15 | 開始されました | Stifel | Buy |
2019-07-02 | アップグレード | Janney | Neutral → Buy |
2019-01-14 | アップグレード | Stephens | Equal-Weight → Overweight |
2018-10-31 | ダウングレード | Craig Hallum | Buy → Hold |
2018-10-17 | 開始されました | Goldman | Neutral |
2018-06-15 | 開始されました | Argus | Buy |
2017-07-13 | 開始されました | Wells Fargo | Market Perform |
2017-02-09 | 開始されました | Citigroup | Buy |
2017-01-18 | 開始されました | Deutsche Bank | Buy |
2016-11-10 | 再開されました | Leerink Partners | Outperform |
2015-01-21 | 繰り返されました | Robert W. Baird | Outperform |
2013-09-20 | アップグレード | Robert W. Baird | Neutral → Outperform |
すべてを表示
Bio Techne Corp (TECH) 最新ニュース
Is Bio-Techne Stock the Right Pick for Your Portfolio Now? - Nasdaq
Bio-Techne Sets Triple Conference Appearance: William Blair, Jefferies, and Goldman Sachs in June - Stock Titan
Bio-Techne to Present at Investor Conferences - PR Newswire
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors - MSN
Cetera Investment Advisers Sells 887 Shares of Bio-Techne Co. (NASDAQ:TECH) - Defense World
Do Wall Street Analysts Like Bio-Techne Stock? - MSN
(TECH) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Bio-Techne (NASDAQ:TECH) Rating Increased to Buy at StockNews.com - Defense World
Ex-Dividend Reminder: Bio-Techne, First Hawaiian and Affiliated Managers Group - Nasdaq
Wednesday Sector Laggards: Healthcare, Materials - Nasdaq
What Makes Bio-Techne Corporation (TECH) a Compelling Addition? - Insider Monkey
ScaleReady awards multiple G-Rex® Grants to leading investigators at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA) - Quantisnow
Bio-Techne at BofA Securities 2025: Strategic Growth Amid Challenges By Investing.com - Investing.com Nigeria
Bio-Techne at BofA Securities 2025: Strategic Growth Amid Challenges - Investing.com
Transcript : Bio-Techne Corporation Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10 - marketscreener.com
Waters Corporation, Avantor, Azenta, Bio-Techne, and Elanco Stocks Trade Up, What You Need To Know - Yahoo Finance
Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025 - The Malaysian Reserve
Bio-Techne to Showcase Next-Generation Solutions for Gene and Ce - GuruFocus
UBS Group Cuts Bio-Techne (NASDAQ:TECH) Price Target to $70.00 - Defense World
When the Price of (TECH) Talks, People Listen - news.stocktradersdaily.com
StockNews.com Downgrades Bio-Techne (NASDAQ:TECH) to Hold - Defense World
Bio-Techne (TECH) Target Price Lowered to $70 by UBS Analyst | T - GuruFocus
UBS Adjusts Price Target on Bio-Techne to $70 From $95, Maintains Buy Rating - marketscreener.com
Bio-Techne outlines 2025 growth drivers with NIH uncertainty and strong Protein Sciences performance - MSN
Beyond the Balance Sheet: What SWOT Reveals About Bio-Techne Corp (TECH) - GuruFocus
Bio-Techne, Kytopen collaborate on integrated cellular engineering workflow - TipRanks
Bio-Techne (TECH) Target Price Lowered by RBC Capital | TECH Sto - GuruFocus
Bio-Techne (TECH) Target Price Lowered by RBC Capital | TECH Stock News - GuruFocus
Benchmark Adjusts Bio-Techne Price Target to $75 From $95 - marketscreener.com
Bio-Techne (TECH): Benchmark Analyst Lowers Target Price but Maintains Buy Rating | TECH Stock News - GuruFocus
BIO-TECHNE (TECH): Analyst Maintains Hold Rating, Lowers Price Target | TECH Stock News - GuruFocus
Bio-Techne to Present at the BofA Securities 2025 Health Care Conference - StreetInsider
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Eng - GuruFocus
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing | TECH Stock News - GuruFocus
Bio-Techne price target lowered to $63 from $72 at RBC Capital - TipRanks
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing - Stock Titan
Bio-Techne Corporation (NASDAQ:TECH) Q3 2025 Earnings Call Transcript - Insider Monkey
Bio-Techne Third Quarter 2025 Earnings: EPS Misses Expectations - simplywall.st
Bio-Techne to Present at the BofA Securities 2025 Health Care Conference | TECH Stock News - GuruFocus
RBC Cuts Price Target on Bio-Techne to $63 From $72, Keeps Sector Perform Rating - marketscreener.com
Bio-Techne Corp (TECH) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amid Global ... - Yahoo Finance
Bio-Techne Corp (TECH) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amid Global ... By GuruFocus - Investing.com Canada
Bio-Techne Corp (TECH) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amid Global Challenges - GuruFocus
Bio-Techne Reports Strong Q3 2025 Revenue Growth - TipRanks
Bio-Techne Q3 2025 Earnings Call Transcript - MarketBeat
Bio-Techne’s Earnings Call: Growth Amid Challenges - TipRanks
Revolutionizing Gene Therapy Protein Expression Potency Assays - Genetic Engineering and Biotechnology News
Bio-Techne Leads Key Proteomic Reagent Markets - Morningstar
Bio-Techne exceeds profit expectations, announces new share buyback plan - MSN
Bio-Techne reports Q3 adjusted EPS 56c, consensus 51c - TipRanks
Bio-Techne’s Resilience and Strong Financial Performance Justify Buy Rating Amid Market Challenges - TipRanks
Bio Techne Corp (TECH) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):